The successful integration of the acquired Biosimilars business dominated the Biocon Biologics growth story last year. In fiscal year 2024-25 (FY25), we have turned our focus to consolidating the acquired business and paving the way for future growth. Our performance in the first quarter of FY25 gives us confidence that we are on the right … Continue reading Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
A Blog by Biocon 